Prime Medicine to Present at Guggenheim Healthcare Talks – Genomic Medicines and Rare Disease Days

Rhea-AI Summary

Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology firm focused on innovative one-time curative genetic therapies, announced that its CEO, Keith Gottesdiener, will present a corporate overview at the Guggenheim Healthcare Talks on April 3, 2023, at 3:55 p.m. ET in New York, NY. A live audio webcast will be accessible in the company’s News & Events section at www.primemedicine.com, with a replay available for 30 days post-event. Prime Medicine uses advanced Prime Editing technology aimed at treating a wide range of diseases by precisely correcting genetic mutations.

CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will present a corporate overview at the Guggenheim Healthcare Talks – Genomic Medicines and Rare Disease Days on Monday, April 3, 2023 at 3:55 p.m. ET in New York, NY.

A live audio webcast of the presentation will be available under “Events & Presentations” in the News & Events section of the Company’s website at www.primemedicine.com. A replay of the webcast will be available on the Prime Medicine website for 30 days following the presentation.

About Prime Medicine
Prime Medicine is a biotechnology company committed to delivering a new class of differentiated, one-time, curative genetic therapies to address the widest spectrum of diseases. The company is deploying Prime Editing technology, a versatile, precise, efficient and broad gene editing technology, which is designed to make only the right edit at the right position within a gene. With the potential to repair approximately 90 percent of known disease-causing genetic mutations across many organs and cell types, medicines based on Prime Editing could offer a one-time curative genetic therapeutic option to a broad set of patients.

Investor Contact
Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
hannah.deresiewicz@sternir.com

Media Contact
Dan Budwick, 1AB
dan@1ABmedia.com

FAQ

What is the date and time of Prime Medicine's corporate overview presentation?

Prime Medicine's corporate overview presentation is scheduled for April 3, 2023, at 3:55 p.m. ET.

Where can I watch the live webcast of Prime Medicine's presentation?

You can watch the live webcast of Prime Medicine's presentation on their website under the News & Events section at www.primemedicine.com.

How long will the webcast replay of Prime Medicine's presentation be available?

The replay of the webcast will be available for 30 days following the presentation.

What technology does Prime Medicine use for its genetic therapies?

Prime Medicine utilizes Prime Editing technology, designed to correct genetic mutations precisely and efficiently.

What is the potential impact of Prime Medicine's therapies?

Prime Medicine's therapies have the potential to repair approximately 90% of known disease-causing genetic mutations across various organs and cell types.